Provectus Biopharmaceuticals

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy drugs for different disease areas based on a class of small molecules called halogenated xanthenes (HXs). The company's lead molecule is Rose Bengal sodium. A second HX molecule has been synthesized. Provectus’ drug discovery and development programs include oncology (clinical stage), dermatology (clinical stage), hematology, infectious diseases, ophthalmology (clinical stage), animal health, and research drugs and drug targets for tissue regeneration and repair, utilizing various routes of administration such as intratumoral (IL), topical (.top), oral (P.O.), inhalation (.inh), intranasal (IN), and intravenous (IV).